Somatostatin

What is Somatostatin?

Somatostatin is an endogenous cyclic peptide hormone that exists in two bioactive isoforms — somatostatin-14 (SST-14) and somatostatin-28 (SST-28) — both cleaved from a common 116-amino-acid precursor (preprosomatostatin) encoded by the SST gene on chromosome 3q28. It is produced and released from the hypothalamus (where it reaches the anterior pituitary via the portal system), from delta (D) cells of the pancreatic islets and gastrointestinal tract, from neurons throughout the central nervous system, and from scattered endocrine cells in the thyroid and adrenal medulla. Somatostatin signals through five G-protein-coupled receptors (SSTR1–SSTR5) that are differentially expressed across tissues and together mediate what is essentially a universal 'off switch' for secretory physiology. It inhibits pituitary growth hormone (and to a lesser extent TSH) release, pancreatic insulin and glucagon secretion, gastric acid and gastrin release, cholecystokinin, secretin, VIP, pancreatic exocrine secretion, and intestinal motility. Its circulating half-life is only 1–3 minutes — rapidly inactivated by ubiquitous peptidases — which is the single most important pharmacokinetic fact about native somatostatin and the reason all chronic clinical therapy uses degradation-resistant analogs (octreotide, lanreotide, pasireotide) rather than the native peptide.

What Somatostatin Is Investigated For

Somatostatin is discussed primarily as a foundational endocrine peptide and as the physiological template behind a clinically important class of drugs, not as a directly prescribable therapy in its native form. The strongest evidence is mechanistic: more than fifty years of work since Brazeau and Guillemin's 1973 isolation have established SST-14 and SST-28 as inhibitory regulators of growth-hormone, pancreatic hormone, and gastrointestinal secretion, acting through the SSTR1–SSTR5 receptor family. Native somatostatin is used clinically in some jurisdictions as a short intravenous infusion for acute variceal hemorrhage and as a peri-operative agent, but the 1–3 minute half-life precludes practical chronic use — which is why the class's clinical footprint is carried by the degradation-resistant synthetic analogs octreotide, lanreotide, and pasireotide (all FDA-approved for acromegaly, neuroendocrine tumor symptom control, and — for pasireotide — Cushing's disease). Somatostatin receptor biology is also the mechanistic basis for modern neuroendocrine-tumor theranostics: DOTATATE-radiolabeled analogs bind SSTR2 on tumor cells for both PET imaging and peptide-receptor radionuclide therapy (Lutathera). The honest caveats: outside the acute variceal-bleeding setting, native SST is not a wellness or longevity peptide; reading about it in the context of the broader peptide scene requires understanding that almost every clinically meaningful action is delivered today by its analogs rather than by the parent hormone.

History & Discovery

Somatostatin's discovery is one of the canonical stories of twentieth-century peptide endocrinology. In the early 1970s, Paul Brazeau — a postdoctoral fellow in Roger Guillemin's laboratory at the Salk Institute — had been assigned the task of isolating the putative growth hormone-releasing factor from ovine hypothalamic extracts, using as a bioassay the release of growth hormone from rat pituitary cells in vitro. The experiments repeatedly showed inhibition rather than release. Rather than discard the anomaly, Guillemin's group reframed the problem and set out to isolate the inhibitor instead. Working from extracts of roughly 500,000 sheep hypothalami, Brazeau, Wylie Vale, Roger Burgus, Nicholas Ling, Madalyn Butcher, Jean Rivier, and Guillemin purified, sequenced, and synthesized the 14-amino-acid cyclic peptide and published the definitive paper in Science on January 5, 1973 — 'Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone.' The peptide was named somatostatin (somatotropin release-inhibiting factor, SRIF). Within months, Siler, VandenBerg, Yen, Brazeau, Vale, and Guillemin had demonstrated inhibition of growth-hormone release in humans as well. This work, along with Guillemin's broader program of hypothalamic releasing-factor isolation, contributed directly to his 1977 Nobel Prize in Physiology or Medicine, shared with Andrew Schally (who independently isolated and sequenced other hypothalamic releasing factors) and Rosalyn Yalow (for radioimmunoassay). Subsequent work in the late 1970s by Pradayrol, Jornvall, Mutt, and colleagues identified the longer 28-amino-acid isoform somatostatin-28, showed it was a co-product of preprosomatostatin processing, and established tissue-specific isoform ratios. The SSTR1–SSTR5 receptor family was cloned in the early 1990s by several groups working in parallel, including Reisine, Bell, Yamada, Epelbaum, and Patel, and the mechanistic pharmacology that followed directly enabled the development of the modern somatostatin-analog drug class — beginning with octreotide (Sandostatin, approved 1988) and extending to lanreotide and pasireotide, and to the theranostic DOTATATE platform now central to neuroendocrine-tumor imaging and peptide-receptor radionuclide therapy.

How It Works

Somatostatin is the body's built-in 'off switch' for hormone secretion. It tells the pituitary to stop releasing growth hormone, tells the pancreas to stop releasing insulin and glucagon, and tells the gut to quiet down its digestive and motility hormones. It does this by binding to five different receptors (SSTR1–SSTR5) that all share the same basic effect of turning down the cellular signaling that drives secretion. The catch is that somatostatin itself is destroyed in the bloodstream within a couple of minutes, so the drugs built from it (octreotide, lanreotide, pasireotide) are engineered versions that last long enough to actually be useful.

Somatostatin is synthesized as a 116-amino-acid precursor (preprosomatostatin) that is processed by prohormone convertases (primarily PC1/3 and PC2) to yield the two bioactive isoforms — somatostatin-14 (SST-14) and somatostatin-28 (SST-28). Tissue-specific processing determines the isoform ratio: SST-14 predominates in the hypothalamus, enteric nervous system, and peripheral nerves; SST-28 predominates in intestinal mucosal cells and retina. Both isoforms contain a disulfide bridge between conserved cysteine residues that creates the characteristic cyclic structure required for receptor binding, and both are rapidly inactivated by dipeptidyl aminopeptidases and endopeptidases in plasma and tissue, yielding a circulating half-life of 1–3 minutes. All five somatostatin receptors (SSTR1–SSTR5) are seven-transmembrane G-protein-coupled receptors encoded by separate genes on different chromosomes. They signal predominantly through Gi/Go proteins, with the dominant shared downstream effect being inhibition of adenylyl cyclase and reduction of intracellular cAMP. Additional signaling mechanisms include activation of phosphotyrosine phosphatases (PTPs) — which mediates cytostatic antiproliferative effects — modulation of mitogen-activated protein kinase (MAPK) signaling, activation of inward-rectifying potassium channels, inhibition of voltage-dependent calcium channels, and regulation of Na+/H+ exchangers and phospholipase A2. The receptor-specific profile of these downstream couplings is a major determinant of tissue-specific effects. Receptor distribution and preference patterns are central to the pharmacology of the field. SSTR2 is heavily expressed on pituitary somatotrophs (growth-hormone-producing cells), on pancreatic alpha cells, on gastrointestinal D cells and enteric neurons, and critically on well-differentiated neuroendocrine tumors — which makes SSTR2 the target of octreotide, lanreotide, and of DOTATATE-based imaging and peptide-receptor radionuclide therapy (PRRT). SSTR5 is also heavily represented on pituitary somatotrophs and especially on corticotroph adenomas in Cushing's disease, which is the mechanistic rationale for pasireotide's expanded-receptor profile (high affinity for SSTR1, 2, 3, and 5). SSTR1, SSTR3, and SSTR4 have broader roles in the central nervous system, immune cells, and tumor biology. Physiologic inhibitory effects span multiple organ systems: in the hypothalamus-pituitary axis, somatostatin inhibits GH and (to a lesser extent) TSH release; in pancreatic islets, it inhibits insulin (beta cell), glucagon (alpha cell), and pancreatic polypeptide release; in the GI tract, it inhibits gastrin, secretin, cholecystokinin, motilin, VIP, and GIP release, slows gastric emptying, inhibits gastric acid secretion, reduces pancreatic exocrine secretion, decreases intestinal motility, and reduces splanchnic and mesenteric blood flow; in the CNS, SST-expressing interneurons provide inhibitory modulation in cortical and hippocampal circuits. The 'universal inhibitor' nickname reflects the breadth of these simultaneous effects.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Somatostatin:

• 01Differential contributions of SST-14 versus SST-28 to tissue-specific physiology — receptor binding affinities differ modestly, but the functional consequences of isoform ratios in brain, gut, and islet are incompletely parsed.
• 02SSTR1, SSTR3, and SSTR4 biology — while SSTR2 and SSTR5 are well characterized because they are the targets of approved drugs, the physiologic and pathologic roles of the other three receptors, and whether subtype-selective agonists or antagonists could be therapeutically useful, remain open questions.
• 03Loss of somatostatin-positive cortical interneurons in Alzheimer's disease and other neurodegenerative conditions is well-documented, but whether restoring somatostatin signaling has a therapeutic effect in CNS disease is unresolved and an active research frontier.
• 04Role of somatostatin in immunity — SSTR expression on lymphocytes and monocytes is established, but the in vivo immunomodulatory role of endogenous somatostatin signaling is not well defined.
• 05Next-generation ligands — chimeric somatostatin/dopamine analogs (dopastatins) and pan-receptor agonists have been explored for refractory acromegaly and Cushing's disease, but the clinical niche relative to existing analogs is still being defined.
• 06Native somatostatin versus octreotide for acute variceal hemorrhage — multiple head-to-head trials suggest rough equivalence, but the optimal choice in specific clinical subsets (Child-Pugh C cirrhosis, renal failure, concurrent vasopressors) is not fully resolved.

Forms & Administration

Native somatostatin has no consumer or wellness formulation. Where it is used therapeutically, it is administered as a continuous intravenous infusion (typical protocols: 250 mcg IV bolus followed by 250 mcg/hour infusion over 2–5 days for acute variceal hemorrhage), exclusively in hospital settings under specialist supervision. In the US, the clinical role for chronic somatostatin-receptor agonism is filled by the synthetic analogs — octreotide (immediate-release SC or monthly LAR IM depot), lanreotide (monthly deep SC depot), and pasireotide (SC or monthly IM depot). Patients interested in somatostatin-receptor biology as a therapy should refer to those analog entries rather than to native peptide. There is no legitimate subcutaneous or home-use administration of native somatostatin.

Common Questions

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions